Tag: Jim Dobbin

The below Parliamentary question was asked by Jim Dobbin on 2014-07-16.

To ask the Secretary of State for Health, pursuant to the Answers of 9 July 2014, Official Report, column 313W, on ovarian cancer and 24 June 2014, Official Report, columns 156-7W, on ovarian hyperstimulation syndrome, if his Department will collect data on the number of women admitted to hospital with ovarian hyperstimulation syndrome (OHSS); if he will take steps to ensure systematic reporting of OHSS from egg sharing and egg donation; if he will make it his policy that ovarian hyperstimulation syndrome be notifiable; and if he will take steps to ensure that women are accurately informed of the risk of hospitalisation from OHSS when considering egg donation or egg sharing procedures.

Jane Ellison

Collection of data relating to treatments regulated by the Human Fertilisation and Embryology Act 1990, as amended, and the recording of serious adverse clinical reactions come within the statutory duties of the Human Fertilisation and Embryology Authority (HFEA).

At its meeting on 9 July 2014, the HFEA agreed a new strategy for 2014-2017, which sets out its regulatory focus. Also at that meeting, the Authority members agreed to give consideration to the collection of additional data when a case of Ovarian Hyperstimulation Syndrome is reported. The HFEA will take expert scientific and medical advice on whether such data collection would be of value and on the feasibility of collecting reliable information.

The papers for the meeting and an audio record of the discussions can be found on HFEA’s website at:

www.hfea.gov.uk/Authority-July-2014.html

The below Parliamentary question was asked by Jim Dobbin on 2014-06-17.

To ask the Secretary of State for Health, with reference to the Answer of 19 January 2012, Official Report, columns 932-3W, how many companies hold licences for the manufacture or distribution of (a) Nitrazepam, (b) Flurazepam, (c) Loprazolam, (d) Lormetazepam, (e) Temazepam, (f) Clonazepam, (g) Medazepam, (h) Midazolam, (i) Zopiclone, (j) Zaleplon, (k) Zolpiden, (l) Eszopiclone, (m) SSRI antidepressants and (n) trycyclic antidepressants; and how many of those licences were issued in the last three years.

Norman Lamb

There are currently 15 products authorised in the United Kingdom containing nitrazepam and 15 different companies authorised to manufacture and distribute them.

There are currently two products authorised in the UK containing flurazepam and one company authorised to manufacture and distribute them.

There are currently two products authorised in the UK containing loprazolam and two different companies authorised to manufacture and distribute them.

There are currently eight products authorised in the UK containing lormetazepam and four different companies authorised to manufacture and distribute them.

There are currently 10 products authorised in the UK containing temazepam and six different companies authorised to manufacture and distribute them.

There are currently six products authorised in the UK containing clonazepam and three different companies authorised to manufacture and distribute them.

There are currently no authorised products in the UK containing medazepam.

There are currently 22 products authorised in the UK containing midazolam and 10 different companies authorised to manufacture and distribute them.

There are currently 17 products authorised in the UK containing zopiclone and nine different companies authorised to manufacture and distribute them.

There are currently two products authorised in the UK containing zaleplon and one company authorised to manufacture and distribute them.

There are currently 21 products authorised in the UK containing zolpidem and 12 different companies authorised to manufacture and distribute them.

There are currently no authorised products in the UK containing eszopiclone.

There are currently 238 products authorised in the UK containing SSRI antidepressants and 57 different companies authorised to manufacture and distribute them.

There are currently 16 products authorised in the UK containing tricyclic antidepressants and 11 different companies authorised to manufacture and distribute them.

One loprazolam, four lormetazepam, two clonazepam, two midazolam, three zopiclone, four zolpidem and 75 SSRI products have been authorised in the last three years.

The below Parliamentary question was asked by Jim Dobbin on 2014-05-02.

To ask the Secretary of State for International Development, what steps she is taking to ensure that her Department’s vaccination programmes reach children with disabilities.

Lynne Featherstone

The UK is a leading advocate for vaccination coverage that ensures that the poorest and most vulnerable groups, including those with disability, have access to essential vaccines. The UK funds the GAVI Alliance, the Global Polio Eradication Initiative and the Measles and Rubella Initiative to conduct supplemental immunisation activities, specifically targeting children who are outside the routine immunisation service delivery system.

The UK’s goal on immunisations is that every child is fully immunised with equitable coverage of core vaccines. In 2011, the UK committed over four years to vaccinate over 80 million children against preventable diseases, including diseases which can lead to disability, through the GAVI Alliance. DFID’s 2014 Annual Report shows we are on track to meet this commitment.

The below Parliamentary question was asked by Jim Dobbin on 2014-04-30.

To ask the Secretary of State for Health, what his policy is on allowing doctors and nurses who have a conscientious objection to supplying contraceptive drugs or devices which act after fertilisation to receive diplomas in sexual and reproductive health.

Jane Ellison

The Faculty of Sexual and Reproductive Healthcare are responsible for decisions on the syllabus of their Diploma, the requirements for entry to the Diploma course, and the award of a Diploma qualification.

The Department understands that their guidelines on the syllabus and on possible conscientious objection have not changed.

The below Parliamentary question was asked by Jim Dobbin on 2014-04-30.

To ask the Secretary of State for Health, if he will take steps to ensure that the Faculty of Sexual and Reproductive Health of the Royal College of Obstetricians and Gynaecologists acts to accommodate doctors and nurses who have a conscientious objection to supplying contraceptive drugs or devices which act after fertilisation receive a diploma in sexual and reproductive health.

Jane Ellison

The Faculty of Sexual and Reproductive Healthcare are responsible for decisions on the syllabus of their Diploma, the requirements for entry to the Diploma course, and the award of a Diploma qualification.

The Department understands that their guidelines on the syllabus and on possible conscientious objection have not changed.

The below Parliamentary question was asked by Jim Dobbin on 2014-05-08.

To ask the Secretary of State for Health, what assessment he has made of the findings of the recent Global Forum on Incontinence into improving health and social care in incontinence.

Norman Lamb

No assessment has been made of the findings of the recent Global Forum on Incontinence (GFI) into improving health and social care in incontinence. However, we applaud the work of the GFI and the work it is doing to improve the health and social care provisions for incontinence, giving patients and care givers a better quality of life.

Responsibility for continence services sit with NHS England and clinical commissioning groups (CCG). CCGs are responsible for commissioning high quality continence services based on an assessment of local need and performance managing their providers in the delivery of high quality services.

The Mandate to NHS England requires it to deliver continued improvements in relation to enhancing the quality of life for people with long-term conditions, including those suffering incontinence, across the five domains of the NHS Outcomes Framework. NHS England will be taking forward a major programme of work through the Primary Care Strategy; it has established a working group on continence care and will provide an update for the All Party Parliamentary Group for Continence Care on 24 June.

To improve standards in continence care, the Department commissioned the National Institute for Health and Care Excellence (NICE) to develop clinical guidelines on the management of urinary incontinence in women (issued in 2006) and faecal incontinence in adults (issued in 2007), which are supported by commissioning tools to support CCGs. In February, NICE published a clinical Quality Standard on Faecal Incontinence, QS54, which describes high-priority areas for quality improvement in this area. NHS England continues to champion the use of Quality Standards with both commissioners and providers.

We believe all patients have the right to be treated with dignity, respect and compassion.

We recognise that continence can impact on every aspect of peoples’ lives and that it often requires a joined approach from both health and social care services. That is why in April the Department published the policy paper, Transforming Primary Care: safe proactive, personalised care for those who need it, which focuses on improving and individualising the management of out of hospital care, directly supporting those with continence problems by creating more integrated health and social care services. This paper has been placed in the Library.

The below Parliamentary question was asked by Jim Dobbin on 2014-05-08.

To ask the Secretary of State for Health, if he will discuss with the Royal College of Obstetricians and Gynaecologists the decision of its faculty of sexual and reproductive health not to allow doctors and nurses who have a conscientious objection to supplying contraceptive drugs or devices which act after fertilisation to receive its diploma in sexual and reproductive health.

Jane Ellison

The Faculty of Sexual and Reproductive Healthcare is responsible for decisions on the syllabus of its Diploma, the requirements for entry to the Diploma course, and the award of a Diploma qualification.

The below Parliamentary question was asked by Jim Dobbin on 2014-05-08.

To ask the Secretary of State for International Development, what steps her Department has taken to reorganise its funding model to ensure that it is encouraging service delivery for complex multiple needs, in line with an intregrated model of healthcare solutions.

Lynne Featherstone

DFID supports work to strengthen health systems and deliver health programmes, helping developing countries to assess and provide for the health needs of its people. This will enable countries to make sound decisions about the delivery of the promotion, prevention and treatment services that are needed.

The below Parliamentary question was asked by Jim Dobbin on 2014-05-08.

To ask the Secretary of State for Foreign and Commonwealth Affairs, what discussions he has had with the government of Pakistan on (a) the fairness of the hearing of Asiya Noreen Bibi who was sentenced to death in 2011 at the provincial Lahore High Court and (b) providing adequate protection to judiciary officials to allow a further hearing to take place.

Hugh Robertson

We regularly raise the issue of blasphemy laws, and their misuse against both Muslims and religious minorities, at the highest levels in Pakistan and press the government to ensure fair trials.We remain concerned about the case of Asia Bibi and would urge the courts in Pakistan to ensure a fair and swift hearing of her appeal due later this month. The Prime Minister, my right hon. Friend the Member for Witney (Mr Cameron) raised our concerns regarding these laws and the need for reforms during the recent visit of Pakistan Prime Minister Nawaz Sharif.